|1.||Lee, Shoei-Sheng: 4 articles (12/2010 - 01/2005)|
|2.||Su, Ming-Jai: 4 articles (12/2010 - 01/2005)|
|3.||Huang, Chien-Chu: 1 article (01/2015)|
|4.||Huang, Kuo-Feng: 1 article (01/2015)|
|5.||Wang, Jia-Yi: 1 article (01/2015)|
|6.||Chen, Gunng-Shinng: 1 article (01/2015)|
|7.||Kuo, Y L: 1 article (01/2012)|
|8.||Lee, A S: 1 article (01/2012)|
|9.||Chen, W P: 1 article (01/2012)|
|10.||Ho, Y J: 1 article (01/2012)|
|1.||Myocardial Ischemia (Ischemic Heart Diseases)
12/01/2010 - "Thaliporphine was found to ameliorate endotoxin-induced circulatory failure and mortality in rodents. "
01/01/2005 - "In conclusion, our results suggest that thaliporphine could be a novel agent for attenuating endotoxin-induced circulatory failure and multiple organ injury and may increase the survival rate. "
10/01/1994 - "Thaliporphine (0.1-100 microM) dose-dependently inhibited nitrite accumulation in macrophages stimulated by interleukin-1 beta (IL-1 beta) whereas nitrite formation induced by tumour necrosis factor alpha was not inhibited. "
01/01/2005 - "Endotoxaemia for 240 min resulted in a bell-shaped time course for the change of serum tumour necrosis factor-alpha (TNF-alpha) level with a peak at 60 min. Pretreatment of LPS-treated rats with 1 mg/kg thaliporphine significantly reduced the serum TNF-alpha level at 60 min. In addition, LPS caused a biphasic change in blood glucose and thaliporphine attenuated the late-phase decrease in blood glucose. "
|4.||Acute Lung Injury
|1.||Interleukin-1beta (Interleukin 1 beta)
|2.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|3.||Morphine (MS Contin)
|4.||Blood Glucose (Blood Sugar)